These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17486454)

  • 1. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
    Nicholson RI; Hutcheson IR; Jones HE; Hiscox SE; Giles M; Taylor KM; Gee JM
    Rev Endocr Metab Disord; 2007 Sep; 8(3):241-53. PubMed ID: 17486454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt signalling via the epidermal growth factor receptor: a role in breast cancer?
    Musgrove EA
    Breast Cancer Res; 2004; 6(2):65-8. PubMed ID: 14979908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
    Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.
    Dorssers LC; van Agthoven T; Brinkman A; Veldscholte J; Smid M; Dechering KJ
    Breast Cancer Res; 2005; 7(1):R82-92. PubMed ID: 15642172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
    Nicholson RI; Hutcheson IR; Britton D; Knowlden JM; Jones HE; Harper ME; Hiscox SE; Barrow D; Gee JM
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):257-62. PubMed ID: 15860268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
    Gee JM; Harper ME; Hutcheson IR; Madden TA; Barrow D; Knowlden JM; McClelland RA; Jordan N; Wakeling AE; Nicholson RI
    Endocrinology; 2003 Nov; 144(11):5105-17. PubMed ID: 12960029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.
    Nicholson RI; McClelland RA; Robertson JF; Gee JM
    Endocr Relat Cancer; 1999 Sep; 6(3):373-87. PubMed ID: 10516852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.
    Yotsumoto F; Oki E; Tokunaga E; Maehara Y; Kuroki M; Miyamoto S
    Int J Cancer; 2010 Dec; 127(11):2707-17. PubMed ID: 20499311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
    Massarweh S; Schiff R
    Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.
    Taylor KM; Vichova P; Jordan N; Hiscox S; Hendley R; Nicholson RI
    Endocrinology; 2008 Oct; 149(10):4912-20. PubMed ID: 18583420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
    McClelland RA; Barrow D; Madden TA; Dutkowski CM; Pamment J; Knowlden JM; Gee JM; Nicholson RI
    Endocrinology; 2001 Jul; 142(7):2776-88. PubMed ID: 11415996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
    Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
    Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
    Nicholson RI; Hutcheson IR; Hiscox SE; Knowlden JM; Giles M; Barrow D; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S29-36. PubMed ID: 16113097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer.
    Hiscox S; Morgan L; Green T; Nicholson RI
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S53-9. PubMed ID: 17259559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
    Schiff R; Massarweh S; Shou J; Osborne CK
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.
    Zhu Y; Sullivan LL; Nair SS; Williams CC; Pandey AK; Marrero L; Vadlamudi RK; Jones FE
    Cancer Res; 2006 Aug; 66(16):7991-8. PubMed ID: 16912174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.